anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bipolar disorder (BD) refers to a type of mood disorder that clinically manifests as both manic or hypomanic episodes and depressive episodes. Bipolar disorder is characterized by high morbidity, recurrence, disability, suicide and comorbidity rate. The first episode often occurs before age 20, with a lifetime morbidity rate ranging from 1.5% to 6.4% . Patients with bipolar disorder spend significantly more time experiencing depressive episodes than manic or mixed symptoms throughout their lives. At the same time, depressive episodes can cause severe psycho-social disabilities, imposing a heavy economic burden on their families and society .

Despite being the first-line recommended treatment for bipolar depression, pharmacotherapy still cannot fully meet the clinical needs. Some patients do not achieve clinical remission even after receiving adequate and full-course pharmacotherapy. Even if clinical remission is achieved, many patients still have residual symptoms, and those in the maintenance phase still face a high risk of relapse. Psychotherapy has been reported to have various benefits such as improving interpersonal communication skills, enhancing cohesion, and building social support systems, and it has been widely used in the treatment of depression. Although psychological intervention plays a crucial role in the treatment of bipolar depression, its application in reality is still limited. One important reason is the shortage of psychological treatment service resources.

The application of virtual reality (VR) technology in the treatment of mental illnesses has overcome the limitations of traditional psychotherapy techniques. It provides a safer, more controllable, and personalized treatment approach, enabling patients to experience environments and events more intuitively and vividly. This study aims to explore the clinical intervention effects of a mental disorder adjuvant treatment software developed by Nanjing XR-Oasis Technology Co., Ltd. on patients with bipolar disorder experiencing depressive episodes. The technology is based on the theoretical frameworks of cognitive behavioral therapy, interpersonal therapy, mental health education, and Naikan therapy, combined with VR technology.
The research team have developed an online family MBI (arm 1) for parents and their children with ADHD. It integrates psychoeducation videos (each 3-7 minutes) with audio mindfulness exercises (each 5-15 minutes). The content includes: (1) mindfulness and attention, (2) mindfulness and physical sensation, (3) mindfulness and parental stress, and (4) mindfulness and parental self-care. The majority of the exercises in the first four modules are for parents, but five of them include guidance for child-parent mindfulness exercises. The fifth module targets children with ADHD and the length of video and audio of mindfulness exercises for children, each last 3-5 mins.
The dose of BYSTOLIC must be individualized to the needs of the patient. For most patients, the recommended starting dose is 5 mg once daily, with or without food, as monotherapy or in combination with other agents. For patients requiring further reduction in blood pressure, the dose can be increased at 2-week intervals up to 40 mg. A more frequent dosing regimen is unlikely to be beneficial.

Renal Impairment

In patients with severe renal impairment (ClCr less than 30 mL/min) the recommended initial dose is 2.5 mg once daily; titrate up slowly if needed. BYSTOLIC has not been studied in patients receiving dialysis [see Clinical Pharmacology ( )]. 12.4

Hepatic Impairment

In patients with moderate hepatic impairment, the recommended initial dose is 2.5 mg once daily; titrate up slowly if needed. BYSTOLIC has not been studied in patients with severe hepatic impairment and therefore it is not recommended in that population [see Clinical Pharmacology ( )]. 12.4
A patch for skin therapy absorbs far infrared rays in the skin through active ingredients including illite and Cheek Cathy so that limps, nerves, and muscles are stimulated and blood circulation is improved. Accordingly, loose muscles can be reduced for a lifting effect. Stationed waste can be discharged blood circulation and limp circulation. Muscles can be released through far infrared rays. The breasts can be lifted. By means of the present invention, the patch of the present invention comprises: a band layer which is made of a cloth member or a film material so as to protect the inside from physical and chemical contact and maintain the shape; a drug layer which includes 3-7% of illite, 30-40% of Cheek Cathy Powder, and 50-70% of liquid silicone and is laminated on the bottom surface of the band layer at a uniform thickness so that far infrared rays and anions are directly penetrated in the skin; an adhesive layer which is laminated at the same width along the edge of the band layer at the same thickness on the same layer as the drug layer so that the drug layer comes in contact with the skin; a peeling layer which adheres on the adhesive layer and drug layer and is made of a film material so as to be removed before being made to adhere on the skin.
A computer-implemented method includes defining a set of multiple stakeholder entities. For each stakeholder entity of the set of stakeholder entities, a corresponding set of multiple health outcomes (Qi) is defined. A set of multiple costs (Cj) is defined. Each cost of the set of costs corresponds to a respective health outcome (Qi) of the set of health outcomes. For each stakeholder entity of the set of stakeholder entities, a value (V) is determined according to the equation V=(ΣinwiQi)/(ΣjmejCj), wherein wi represents a set of numerical weights and ej represents a set of episodes associated with a particular cost to create a set of values (V). A numerical value (V′) optimal to the set of stakeholder entities is determined from the set of values (V).
Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein. Prostate-specific membrane antigen (PSMA) is a 120 kDa protein expressed in prostate tissues and was originally identified by reactivity with a monoclonal antibody designated 7EII-C5 (Horoszewicz et al., 1987, Anticancer Res. 7:927-935; U.S. Pat. No. 5,162,504). PSMA is characterized as a type II transmembrane protein sharing sequence identity with the transferrin receptor (Israeli et al., 1994, Cancer Res. 54:1807-1811).
Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
The process for the isolation of simmondsins from jojoba meal is disclosed. Simmondsins are first extracted from defatted jojoba meal with water. After separation from the meal, this water extract is subsequently dried, leaving the simmondsins in the resulting solid. The simmondsins may then be preferentially extracted from the dried water extract by contact with a first ethanolic solvent, forming a first solvent fraction containing simmondsins therein. The first solvent fraction, which is a substantially protein-free concentrate of simmondsins, may be separated from the solid phase, and the ethanolic solvent may then be readily removed, for example, by drying. Residual simmondsins remaining in the meal following extraction with the first ethanolic solvent may also be recovered by a second extraction with ethanolic solvent. Optionally, simmondsin and its analogs, simmondsin ferulate, demethylsimmondsin, and didemethylsimmondsin, may be separated in substantially pure form from the extracts by reverse-phase HPLC.
Individuals who screen positive will all move forward to receive the intervention. This intervention includes partnering with community-based organizations to deliver financial education, connection to resources, and counseling tailored to individual patients and spouses for 6-months.
The present invention provides a composition and method useful for creating a class of compounds that provide an emollient effect to the skin. The base formulation includes mixtures of certain oils that have high concentrations of Linoleic Acid, an essential fatty acid. Other oils are chosen which have high concentrations of Gamma-Linolenic Acid, Ricinoleic Acid and Oleic Acid. We have found that the incorporation of dl-alpha-tocopheryl and dl-alpha-tocopherol (vitamin E) improves the formulation and provides an anti-oxidative effect which preserves the end product and provides for a longer shelf life. The method disclosed creates free fatty acids, utilizing base catalyzed trans-esterification, inter-esterification and intra-esterification. The final products are lipid compounds which aid in treating dry skin conditions caused by deficiencies in Linoleic Acid or other fatty acids.
A cannabinoid-humic substances composition is provided. The cannabinoid-humic substances composition includes a cannabinoid and humic substances perforated by voids. The cannabinoid is complexed with humic substances and fixed in the voids. A method for making the cannabinoid-humic substances composition is also provided. The method includes supplying (a) humic substances having a structure that is perforated by voids and (b) a cannabinoid. Once the cannabinoid is complexed with the humic substances, the cannabinoid-humic substances composition becomes water soluble.
Aging is associated with declines in both cellular and humoral immunity. A consistent observation of the aging immune system is a change in T cells. Another possible mechanism of diminished cellular immunity associated with age includes accelerated lymphocyte apoptosis. Enhanced lymphocyte apoptosis may play an important role in the pathogenesis of HIV disease. This study will use healthy volunteers to confirm and expand upon such observations. Samples from these volunteers will serve as controls to those from the HIV-infected participants of A5015 (a comparison study of 2 age-differentiated cohorts to determine potential mechanisms that might contribute to accelerated HIV-disease progression that is associated with aging).

This is a non-treatment study; however, volunteers receive hepatitis A and tetanus vaccinations. Numbers of phenotypically naive CD4+ cells (CD45RA+/CD62L+) are compared between healthy, HIV-seronegative volunteers and HIV-seropositive patients of A5015. An array of assays to assess baseline differences in immune function between these study populations are performed. Expression of markers of activation are compared by measuring the coexpression of HLA-DR+/CD38+ and CD28+ on CD4+ and CD8+ lymphocytes between these populations. To investigate possible age-associated differences in apoptosis, Fas (CD95+) expression is measured on CD4+ and CD8+ T cells by flow cytometry, and spontaneous apoptosis is assessed using the propidium iodide method. DTH hypersensitivity to skin test antigens, lymphocyte proliferation to mitogens, soluble antigens, recall antigens, and neoantigens are compared between the 2 populations. Antibody responses to vaccination with tetanus and hepatitis A are assessed. Finally, thymic size as measured by CT scan and the frequency of T cells that contain TRECs is compared between these 2 populations.
A class of substituted azetidine, pyrrolidine and piperidine derivatives of formula (I) are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1D.alpha. receptor subtype relative to the 5-HT1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D  receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D  receptor agonists, wherein Z represents an optionally substituted six-membered heteroaromatic ring selected from pyridine, pyrazine, pyrimidine and pyridazine; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 4 carbon atoms, optionally substituted in any position by one or more substituents selected from fluoro and hydroxy; T  represents nitrogen or CH; U represents N or CR2. V = O, S or NR3. M & R are as defined in the application.
Colorectal cancer is the second leading cause of cancer-related death in North America. Patients with metastatic colorectal cancer generally have limited life expectancy, however, a small number of patients with liver-only metastases could potentially be cured following surgical resection of metastases. Patients and their family strongly feel that there is an unmet need for a more effective treatment in metastatic colorectal cancer to improve disease response rate and thereby curative surgery. Recent evidence suggest that a triplet chemotherapy regimen, FOLFOXIRI plus bevacizumab has been associated with higher response rates. The CONVERSION trial will evaluate the rate of conversion from unresectable to resectable liver metastases in patients with liver-only metastatic colorectal cancer treated with FOLFOXIRI-bevacizumab. Furthermore, this study will assess disease control rate, survival, quality of life and association between various biomarkers including an early FDG-PET/CT response and curative surgery. Thirty-two eligible patients will be recruited at the two major cancer centers in Saskatchewan. Patients will receive FOLFOXIRI-bevacizumab every two weeks for a total of 12 cycles and will undergo periodic imaging studies. The resectability of liver metastases will be assessed by a multidisciplinary team comprised of surgeons, radiologists, and oncologists. This study will be helpful to establish a standard chemotherapy regimen for patients with liver-only metastatic colorectal cancer and to determine the role of FDG-PET/CT scan and other biomarkers in predicting curative surgery. Complete resection of metastases will allow such patients to discontinue chemotherapy and live a normal life.
Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
Moexipril hydrochloride is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone, see PRECAUTIONS). 

Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin hypertension. As is the case with other ACE inhibitors, however, the antihypertensive effect of moexipril is considerably smaller in black patients, a predominantly low-renin population, than in non-black hypertensive patients.
PURPOSE: To manifest instantaneous cardiovascular responses similar to those in aerobic activities by dosing a motion simulant (ESATMβ-agonist) to a mammal by a closed system drug delivery unit, controlling injection into the blood flow. CONSTITUTION: Physical fluctuating factors (e.g. heart rate, blood pressure, arrhythmia, ischemia, e.g. ST segment deflection) are monitored, dosage of ESATMβ-agonist (Z in formula I: hydroxy) is determined, while the closed delivery system composed of the microprocessor and software functionally connected to the physiological monitor sensor and ion migrating delivery unit (they are in touch with patient, see Fig.) determines dosage of ESATMβ-agonist to automatically control it. The microprocessor 1 controls the amount of drug supplied from the drug storage vessel positioned in the electrode 3a (one electrode is the indifferent electrode 3b) to the patient by the electric current ratio supplied by the signal driver controller, hence the percutaneous ion permeator 3.
Incidental parathyroidectomy (IP) is a complication seen at varying rates after thyroid surgery, and its relationship with postoperative hypocalcemia has not been clarified. In this study, our goal was to identify the frequency and risk factors for IP in a large patient cohort and assess its correlation with postoperative hypocalcemia. A total of 4052 patients who underwent thyroid surgery between 2008 and 2020 were reviewed retrospectively. The patients were divided into two groups, the IP and non-IP groups, and compared in terms of demographics, surgical procedures, pathological diagnosis, and specimen weight. The relationships between IP and hypocalcemia were also evaluated. There were 587 (14.5%) IPs out of 4052 cases. In these patients, mostly one gland was removed (84.6%), and 23.2% of these glands were intrathyroidal. The rate of transient hypocalcemia was 39.9%, and that of permanent hypocalcemia was 1.7%. Female gender, malignancy, lower preoperative thyroid volume, presence of central lymph node dissection, lower specimen weight, presence of autotransplantation and capsule invasion in malignant cases were determined to be risk factors for IP. After excluding hemithyroidectomy and autotransplantation, transient and permanent hypocalcemia were found to be significantly higher in cases with IP (p < 0.001). Multivariate analysis showed that female sex, no multinodular goiter, central dissection, and low thyroid volume were risk-adjusted independent variables. Our findings highlight the significant role of IP in postoperative hypocalcemia. Given that most IPs are located in the perithyroidal region, precise surgical dissection is vital to preserve parathyroid gland function and prevent IP and subsequent hypocalcemia.
BACKGROUND AND OBJECTIVES: People with diabetic peripheral neuropathy (DPN) report fluctuating foot symptoms. This study used ecological momentary assessment to: (1) compare foot symptoms between days, time points and periods with/without preceding physical activity or pain medication; and (2) determine relationships between symptoms and endogenous pain modulation.
METHOD: Ten low-active Australian adults with probable DPN underwent temporal summation of pain (TSP) and conditioned pain modulation (CPM) then completed mobile phone surveys five times daily for seven days, where they recorded the intensity of six foot symptoms and whether they performed physical activity or consumed pain medication in the preceding three hours.  RESULTS: All foot symptoms except numbness were greater in periods following physical activity, whereas periods following pain medication showed greater shooting pain. TSP showed very large correlations with sensitivity to touch, burning pain, shooting pain and prickling/tingling.  DISCUSSION: General practitioners should be aware that physical activity might exacerbate symptoms of DPN when encouraging their patients to be active.
Irritable bowel syndrome (IBS); It is one of the most frequently diagnosed gastrointestinal diseases, defined by the presence of altered bowel habits, abdominal pain, and discomfort in the absence of another causative disease. The research will be planned on 72 individuals between the ages of 18-65 who were diagnosed with IBS at Istanbul Medipol University Çamlıca SUAM Gastroenterology Polyclinic. Patients will be divided into 3 groups; High-intensity interval training and a disease-specific nutrition program for the first group, and a disease-specific nutrition program for the second group; Basic Body Awareness Therapy (BBAT) and a disease-specific nutrition program will be given, while the control group will be given only a disease-specific nutrition program. Evaluations will be made immediately before and after treatment. The first experimental group will be asked to walk with high-intensity interval training, which the investigators plan for 30 minutes, 4 days a week for 8 weeks. TBFT will be applied to the second experimental group every day of the week. The application will be done face to face one day a week, and the patient will be asked to do it himself on the other days, and the sessions will last approximately 30 minutes. In addition, all patients will be asked to follow the nutrition program determined by the dietician. Participants' sociodemographic information, IBS disease type and medications used will be recorded. In order to collect data for both the intervention groups and the control group immediately before and after the study; 6 Minute Walk Test (6MWT), posture analysis, muscle shortness test for large muscle groups in the lower and upper extremities, International Physical Activity Questionnaire Short Form (IPAQ-SF), Diet Compliance Questionnaire Form, Bristol Stool Scale Form, Gastrointestinal Symptom Assessment Scale (GSDS). ), Pittsburgh Sleep Quality Index (PSQI), IBS Quality of Life Scale (IBS-QOL), Morningness-Eveningness Questionnaire (SAA), Psychological Well-Being Scale (PIOS) and Body Awareness Questionnaire (VFA) will be used. Physiotherapy and rehabilitation applications of aerobic exercise and TBFT have been rarely studied in the literature on patients with IBS; this will be the first and original study, as there are no studies examining the effects of a disease-specific nutrition program on gastrointestinal symptoms, quality of life, sleep quality and well-being.
Particulate compositions containing an active agent in combination with a bile salt or a polymer of a bile salt are described herein. The active agent may be the bile salt or polymer thereof. In one embodiment, the active agent is encapsulated in, coated onto, or incorporated into a matrix forming a polymeric microparticle or nanoparticle. The bile salt can be coated onto the surface of the particle or incorporated into a coating which is coated onto the surface of the particle. In another example, polymeric microparticles having active agent encapsulated therein can be dispersed in a bile salt emulsion. Alternatively, the bile salt can be incorporated into the polymeric microparticle or nanoparticle, for example, dispersed throughout the polymeric microparticle or nanoparticle or encapsulated in the core, where active agent(s) is in the core, the polymeric matrix, the coating, or a combination thereof. Active agent can be encapsulated in the core and/or can be dispersed throughout the microparticle. In another embodiment, the active agent is encapsulated in a microparticle, coating, layer, core, emulsion or dispersion formed of a polymer of a bile salt, such as polydeoxycholic acid. Suitable active agents include therapeutic, diagnostic, and/or prophylactic agents. The compositions are formulated for oral administration or administration to a mucosal (nasal, pulmonary, rectal, vaginal, buccal, sublingual).